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Introduction
Nevoid basal cell carcinoma syndrome is an auto-
somal dominant inherited disease. The prevalence of 
the syndrome is estimated to be about 1 in 60,000. 
One of the major manifestations in these patients is 
multiple odontogenic keratocysts (OKCs) of the jaws, 
in addition to multiple nevus-like pigmentations 
which represent basal cell carcinomas. Other com-
monly seen clinical features include calcification of 
the falx cerebri, bifid ribs, palmar/plantar pits, 
and benign neoplastic changes in the brain.1 Genetic 
alterations, including mutations, insertions and 
deletions, in the PTCH gene have been reported. 
Here, we document a case of nevoid basal cell carci-
noma syndrome in a 15-year-old girl who developed 
Nevoid basal cell carcinoma syndrome (also named Gorlin-Goltz syndrome) is a rare 
disease. Commonly seen features include multiple odontogenic keratocysts (OKCs), 
nevus-like basal cell carcinoma, and bifid ribs. Genetic alterations of the PTCH1 gene 
are associated with the disease. Herein, we report the case of a 15-year-old girl 
who presented with multiple OKCs, a bifid rib, ectopic calcification of the falx cer-
ebri, and an arachnoid cyst of the cerebrum. No basal cell carcinoma was identified. 
In addition, a search for genetic alterations was performed on the patient. We 
identified a genetic mutation of CT in exon 12 (c.1686 bp) and a GC mutation in 
intron 13 (g.91665 bp) of the PTCH1 gene. Although a similar mutation in exon 12 was 
reported in a literature search, the mutation in intron 13 has not previously been 
reported. The patient has continued to be followed-up almost 3 years after the surgery 
with no recurrence of the OKCs or development of basal cell carcinoma.
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three consecutive OKCs in the mandible. In addition, 
the presence of a bifid rib and calcification of the 
falx cerebri were discovered. Computed tomography 
scan of the brain demonstrated a 1.5-cm arach-
noid cyst in the right frontal lobe of the brain. A 
genetic sequencing study was performed on the 
patient to search for mutations in the PTCH gene.
Case presentation
The patient was a 15-year-old high school female 
student who came to the Oral and Maxillofacial 
Surgery clinic at Chung Shan Medical University 
Hospital in May 2006 with the chief complaint of 
swelling at the lower left anterior mucolabial fold 
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for several months. An intraoral examination showed 
swelling of the lower anterior mucolabial fold, and 
also a missing lower left canine (#33). Extraorally, 
multiple nevus-like macules were noted across the 
face (Fig. 1). A panoramic radiograph was taken, and 
an impacted mandibular canine (#33) was noted to 
be surrounded by a well-defined radiolucent lesion 
and divergent roots of the first premolar (#34) and 
lateral incisor (#32) (Fig. 2). A clinical provisional 
diagnosis of a dentigerous cyst was rendered. The 
patient was scheduled to have the cyst enucleated, 
and the impacted #33 tooth was removed in July 2006. 
Histopathological evaluation of the specimen showed 
a cyst lined with keratinized stratified squamous 
epithelium and prominent palisading basal cells, 
suggestive of OKCs. In the meantime, radiographic 
examinations showed ectopic calcification of the falx 
cerebri (Fig. 3) and a bifid right fourth rib (Fig. 4). In 
addition, brain magnetic resonance imaging showed 
a possible arachnoid cyst with a greatest dimension 
of 1.5 cm in the right frontal lobe (Fig. 5). A full 
spinal radiograph showed marked scoliosis along the 
T spine (Fig. 6). Thus, a final diagnosis of nevoid 
basal cell carcinoma syndrome was made.
Fig. 1 Multiple pigmented macules and papules on the 
face of the patient.
Fig. 2 Initial panoramic radiograph shows a well-defined 
radiolucent lesion (arrows) associated with an impacted 
left mandibular canine (#33).
Fig. 3 Skull radiograph shows calcification of the falx 
cerebri (arrow).
Fig. 4 Chest posteroanterior radiograph shows a bifid 
deformity of the fourth rib on the right side (arrow).
After surgery, the patient was placed under 
close radiographic follow-up. Three months later dur-
ing follow-up, well-defined radiolucent lesions were 
noted around the left and right mandibular third mo-
lars (Fig. 7), although no clinical signs or symptoms 
were observed. Our clinical impression was OKCs for 
both lesions, and the patient was arranged to re-
ceive another cyst enucleation. Histo pathologic eval-
uation of both specimens from the left and right 
lower mandibular third molar regions confirmed the 
clinical impression (Fig. 8). Almost 3 years after 
surgery, the patient continues to be under routine 
follow-up with panoramic radiographs, and no re-
currence of OKCs has been noted, or basal cell carci-
noma detected.
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Fig. 5 Magnetic resonance imaging of the brain shows a 
1.5-cm arachnoid cyst in the right frontal lobe (arrow).
Fig. 6 Full-spine radiograph shows marked scoliosis at 
the T spine region.
Fig. 7 Additional well-defined radiolucent lesions noted 
during follow-up in the #38 and #48 areas (arrows).
Fig. 8 Histopathological features show a cyst lined by 
parakeratinized stratified squamous epithelium with the 
notable presence of a satellite cyst.
the patient, and genomic DNA was prepared using 
a Blood Genomic DNA Purification Kit (GeneMark 
Technology, Tainan, Taiwan). The genomic DNA was 
then sequenced. Results showed a transition of CT 
in exon 12 (c.1686 bp) and a GC in intron 13 
(g.91665 bp) (Fig. 9).
Discussion
Nevoid basal cell carcinoma syndrome is also 
termed Gorlin syndrome. It is an autosomal domi-
nant inherited condition.1 The chief components 
are multiple basal cell carcinomas of the skin, 
OKCs, intracranial calcification, rib and vertebral 
anomalies, and intracranial neoplastic change,1 as 
presented in our case. Although no basal cell carci-
noma was diagnosed in our case, she had many ne-
vus-like papules on her face and thus will be closely 
followed-up.
Development of this disease is linked to muta-
tions in PTCH, a tumor suppressor gene that was 
mapped to chromosome 9q22.1−22.33.2−5 The PTCH 
protein is the receptor for sonic hedgehog (SHH), a 
secreted molecule implicated in the formation of 
embryonic structures and in tumorigenesis. There 
are 24 exons in the PTCH gene, and genetic altera-
tions including mutations, insertions and deletions 
have been reported, mostly in exons 10, 11, 12, 
13, 14, 17 and 21. For example, mutation screen-
ing in a nevoid basal cell carcinoma patient showed 
a novel nonsense mutation in PTCH (c.1136 C
G; p.Ser383X).6 In an Italian study, 13 novel muta-
tions were reported, including p.T230P, p.F505_
L506delinsLR, and many others.4 Marsh et al.3 used 
denaturing high-performance liquid chromatography 
to screen for PTCH mutations in 28 nevoid basal 
cell carcinoma cases, and found protein truncations 
(n = 10) and missense or insertion-deletion (n = 4) 
Since different mutations of the PTCH gene 
have been reported in the literature with syndromic 
OKCs, a genetic study on mutations of the PTCH 
gene was performed. Whole blood was drawn from 
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mutations in 14 of 28 (50%) cases, while an addi-
tional case carried an unclassified variant, c.2777 
GC. Among the mutations, 13 of the variants 
were novel, and the mutation frequency was simi-
lar in inherited and de novo cases. Gu et al.7 inves-
tigated 10 non-syndrome associated keratocysts and 
two cases associated with Gorlin syndrome. Four 
novel and one known PTCH mutations were identi-
fied in five individual patients, including two germ-
line mutations (2619 CA, and 1338_1339insGCG) 
in two cysts associated with Gorlin syndrome, and 
three somaticmutations (3124_3129dupGTGTGC, 
1361_1364delGTCT, and 3913 GT) in three non-
syndromic cysts. In another study, three Chinese 
families with sporadic OKCs and nevoid basal cell 
carcinomas were enrolled, and a mutation analysis 
was performed by amplifying all exons of the PTCH 
gene and sequencing the products. The results identi-
fied three novel germline mutations in PTCH, includ-
ing a missense mutation (p.S1089P) in a sporadic 
case, a nonsense mutation (p.Q160X) in a syndromic 
OKC, and a de novo mutation (c.768_777delGACA-
AACTTC) in another syndromic OKC.8 Besides ge-
netic mutations, many isoforms of PTCH messenger 
(m)RNA were identified involving exons 1−5, exon 
10, and a novel exon 12b.9 Since the PTCH product 
serves as a receptor for SHH, the expressions of PTCH 
and SHH were detected in 18 sporadic and four 
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Fig. 9 Genomic DNA obtained from the patient for the PTCH gene sequencing procedure. A transition of CT was 
observed in exon 12 (c.1686 bp) (in red) and a GC in intron 13 (g.91665 bp) (in red).
nevoid basal cell carcinoma-associated OKCs, and 
seven control gingivae by reverse-transcriptase 
polymerase chain reaction.10 However, no muta-
tions were identified in the four nevoid basal cell 
carcinoma-associated OKCs bydirect sequencing.10
A mutation of c.1686 bp CT translating an 
A562A silent mutation in exon 12 was detected in 
our case. Exon 12 encodes the transmembrane do-
main 5 of the PTCH gene and serves as a sterol-
sensing domain. However, this mutation was not 
specific for the development of nevoid basal cell 
carcinoma. The same mutation was not only reported 
in nevoid basal cell carcinoma,11 but also in alveolar 
rhabdomyosarcomas,12 embryonal rhabdomyosar-
comas,12 medulloblastomas,13 basal cell carcinomas 
from xeroderma pigmentosa,14 and squamous cell 
carcinomas.15
Intronic aberrations of the PTCH gene have pre-
viously been reported in many different diseases, 
including basal cell carcinoma (introns 3, 7 and 19),16 
nevoid basal cell carcinoma (introns 5, 6, 7, 9, 10, 
17 and 18),11,17−22 multiple self-healing squamous 
epitheliomas (intron 8),23 germline DNA of nevoid 
basal cell carcinoma (intron 9),24  medulloblastomas 
(introns 5 and 9),25,26 Bowen’s disease  (introns 10 
and 15),27 breast carcinomas (intron 10),28 rhabdomy-
osarcomas (introns 10, 15 and 17),12 basal cell car-
cinomas (introns 1, 8, 9, 12, 15 and 19),16,29−32 and 
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medulloblastomas (intron 17).13 In our case, a sec-
ond mutation was found, a GC at g.91665 bp in 
intron 13, which has not been previously reported. 
Whether there is any significant functional distur-
bance due to this intronic mutation remains to be 
studied.
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